Key facts
- It has raised $460K; the latest was Seed Round in Mar 2026.
- Notable investors include Techstars, National Institutes of Health, Frontline Ventures, Minnesota Department of Employment and Economic Development, National Institute on Drug Abuse (NIDA) — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Neurotype
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurotype are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurotype
Developer of a neurofeedback-based medical platform designed to support recovery from substance use disorders by detecting and addressing brain responses to triggers such as cravings. The company offers non-invasive electroencephalography brain sensing, visual evoked potential analysis, and personalized neurofeedback reports, enabling clinicians and treatment specialists to quantify craving risks and guide targeted interventions that support sustained recovery.
- Sector
- Healthcare
- HQ
- Minneapolis, MN, United States
- Founded
- 2019
- Employees
- 2
- Website
- neurotype.io/
- Ownership
- Privately Held (backing)
Neurotype doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurotype shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurotype in its N-PORT filings yet. We sweep new filings monthly.